Startups 

Omivera is a chemical proteomics company based in Leiden, dedicated to helping scientists overcome one of the biggest challenges in kinase inhibitor development: the lack of physiologically relevant selectivity data. With our patented CellEKT platform, we can help to better understand the drug responses of kinase inhibitors in live cells. We provide accurate, biologically relevant selectivity profiles starting from lead optimization and throughout the drug-development process. Our goal is to help our clients reduce clinical attrition rates and accelerate the development of safer, more effective kinase inhibitors.